Exagen Inc Stock Fundamentals
| XGN Stock | USD 1.87 0.03 1.58% |
Exagen Inc fundamentals help investors to digest information that contributes to Exagen's financial success or failures. It also enables traders to predict the movement of Exagen Stock. The fundamental analysis module provides a way to measure Exagen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Exagen stock.
Exagen |
Exagen Inc Company Shares Outstanding Analysis
Exagen's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Exagen Shares Outstanding | 17.37 M |
Most of Exagen's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Exagen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Exagen Inc has 17.37 M of shares currently outstending. This is 90.38% lower than that of the Biotechnology sector and 87.83% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 96.96% higher than that of the company.
Exagen Inc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Exagen's current stock value. Our valuation model uses many indicators to compare Exagen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Exagen competition to find correlations between indicators driving Exagen's intrinsic value. More Info.Exagen Inc is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Exagen by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Exagen's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Exagen's earnings, one of the primary drivers of an investment's value.Exagen Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exagen's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exagen could also be used in its relative valuation, which is a method of valuing Exagen by comparing valuation metrics of similar companies.Exagen is currently under evaluation in shares outstanding category among related companies.
Exagen Fundamentals
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.45) % | ||||
| Operating Margin | (0.37) % | ||||
| Current Valuation | 14.65 M | ||||
| Shares Outstanding | 17.37 M | ||||
| Shares Owned By Insiders | 28.33 % | ||||
| Shares Owned By Institutions | 58.72 % | ||||
| Number Of Shares Shorted | 4.22 K | ||||
| Price To Book | 1.12 X | ||||
| Price To Sales | 0.49 X | ||||
| Revenue | 52.55 M | ||||
| Gross Profit | 21.35 M | ||||
| EBITDA | (20.67 M) | ||||
| Net Income | (23.69 M) | ||||
| Cash And Equivalents | 76.39 M | ||||
| Cash Per Share | 4.70 X | ||||
| Total Debt | 23.72 M | ||||
| Debt To Equity | 0.55 % | ||||
| Current Ratio | 9.30 X | ||||
| Book Value Per Share | 1.33 X | ||||
| Cash Flow From Operations | (14.46 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (1.34) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 174 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 33.01 M | ||||
| Total Asset | 56.94 M | ||||
| Retained Earnings | (279.22 M) | ||||
| Working Capital | 35.94 M | ||||
| Net Asset | 56.94 M |
About Exagen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Exagen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exagen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exagen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Exagen operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 219 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Exagen Piotroski F Score and Exagen Altman Z Score analysis. Note that the Exagen Inc information on this page should be used as a complementary analysis to other Exagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Exagen Stock analysis
When running Exagen's price analysis, check to measure Exagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exagen is operating at the current time. Most of Exagen's value examination focuses on studying past and present price action to predict the probability of Exagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exagen's price. Additionally, you may evaluate how the addition of Exagen to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Exagen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.